MX2020005041A - Agonistas parciales de interleucina-2. - Google Patents

Agonistas parciales de interleucina-2.

Info

Publication number
MX2020005041A
MX2020005041A MX2020005041A MX2020005041A MX2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A MX 2020005041 A MX2020005041 A MX 2020005041A
Authority
MX
Mexico
Prior art keywords
muteins
interleukin
partial agonists
sub
useful
Prior art date
Application number
MX2020005041A
Other languages
English (en)
Inventor
Christopher K Garcia
Sonia S Majri
Caleb R Glassman
Leon Lih- Ren Su
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2020005041A publication Critical patent/MX2020005041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En este documento se proporcionan, entre otras cosas, muteínas de interleucina 2 (IL-2) de humano o variantes de las mismas. En particular, en este documento se proporcionan muteínas de IL-2 que tienen una capacidad de unión disminuida para IL-2R?. Tales muteínas de IL-2 son útiles, por ejemplo, como agonista parcial de IL-2 en aplicaciones donde es útil la reducción o inhibición de una o más funciones de IL-2 y/o IL-15 (por ejemplo, en el tratamiento de enfermedades o afecciones autoinmunes). También se proporcionan ácidos nucleicos que codifican tales muteínas de IL-2, métodos para hacer tales muteínas de IL-2, composiciones farmacéuticas que incluyen tales muteínas de IL-2 y métodos de tratamiento utilizando tales composiciones farmacéuticas.
MX2020005041A 2017-11-21 2018-11-20 Agonistas parciales de interleucina-2. MX2020005041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589497P 2017-11-21 2017-11-21
PCT/US2018/062122 WO2019104092A1 (en) 2017-11-21 2018-11-20 Partial agonists of interleukin-2

Publications (1)

Publication Number Publication Date
MX2020005041A true MX2020005041A (es) 2020-10-12

Family

ID=66631137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005041A MX2020005041A (es) 2017-11-21 2018-11-20 Agonistas parciales de interleucina-2.

Country Status (13)

Country Link
US (2) US20200299349A1 (es)
EP (1) EP3713592A4 (es)
JP (2) JP7464278B2 (es)
KR (1) KR20200086722A (es)
CN (1) CN111615396A (es)
AU (2) AU2018372167B2 (es)
BR (1) BR112020009920A2 (es)
CA (1) CA3082904A1 (es)
IL (1) IL274723A (es)
MX (1) MX2020005041A (es)
RU (1) RU2020120145A (es)
SG (1) SG11202004581PA (es)
WO (1) WO2019104092A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
MX2020001332A (es) 2017-08-03 2020-09-09 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use
CN115362168A (zh) * 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
MX2023010926A (es) * 2021-03-31 2023-09-27 Hanmi Pharmaceutical Co Ltd Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo.
EP4366782A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Conjugates of checkpoint inhibitors with il-2, and uses thereof
CA3224147A1 (en) 2021-07-09 2023-01-12 Vijaya Raghavan PATTABIRAMAN Antibody conjugates and manufacture thereof
WO2023281482A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
US20240158537A1 (en) 2021-07-09 2024-05-16 Bright Peak Therapeutics Ag Synthetic il-7 and il-7 immunocytokines
US20240132563A1 (en) 2022-02-23 2024-04-25 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024044716A2 (en) * 2022-08-26 2024-02-29 Sonoma Biotherapeutics, Inc. Tethered interleukin-2 recombinant receptors and methods of use
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
EP1846020B1 (en) * 2005-01-27 2013-08-21 Novartis Vaccines and Diagnostics, Inc. Methods for treating renal cell carcinoma
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
KR102349549B1 (ko) * 2010-11-12 2022-01-11 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CA2860170C (en) * 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
BR112016018288A2 (pt) * 2014-02-06 2017-10-10 Hoffmann La Roche proteínas de fusão de interleucina 2 e uso das mesmas
CA2946398A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2

Also Published As

Publication number Publication date
EP3713592A1 (en) 2020-09-30
BR112020009920A2 (pt) 2020-12-15
EP3713592A4 (en) 2022-01-12
KR20200086722A (ko) 2020-07-17
AU2024200355A1 (en) 2024-03-21
CN111615396A (zh) 2020-09-01
RU2020120145A (ru) 2021-12-22
AU2018372167A1 (en) 2020-06-11
JP2024079749A (ja) 2024-06-11
CA3082904A1 (en) 2019-05-31
JP7464278B2 (ja) 2024-04-09
IL274723A (en) 2020-07-30
SG11202004581PA (en) 2020-06-29
WO2019104092A1 (en) 2019-05-31
US20200299349A1 (en) 2020-09-24
AU2018372167B2 (en) 2023-12-07
US20210269498A1 (en) 2021-09-02
JP2021508252A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2020005041A (es) Agonistas parciales de interleucina-2.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
CN106659757A8 (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
PH12020551261A1 (en) Il-15 conjugates and uses thereof
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
NZ736560A (en) Proteins specific for cd137
MX2022007754A (es) Nuevos agonistas de il2 y metodos de uso de estos.
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2010003574A (es) Anticuerpos il-23.
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
EP3957723A3 (en) Engineered ligase variants
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2021015761A (es) Polipeptidos.
PH12021551534A1 (en) Antibody against human il-4ra and use thereof
WO2018042385A3 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX2021005593A (es) Miméticos de interleucina dividida y sus usos.
MX2020009733A (es) Composiciones.
EP4032539A4 (en) IMMUNOCYTOKINE WITH HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15R-ALPHA
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения